Continuous Bioprocessing Challenges

Publication
Article
Pharmaceutical TechnologyPharmaceutical Technology-05-15-2014
Volume 2014 eBook
Issue 2

What challenges do biopharmaceutical manufacturers face when deciding to move from a fed batch process to a continuous process?

What challenges do biopharmaceutical manufacturers face when deciding to move from a fed batch process to a continuous process? Stéphanie Dubois, cell culture laboratory manager and application specialist at Pall Life Sciences, describes challenges and explains how alternative types of perfusion bioreactors can simplify the process.

Download

Pharmaceutical Technology’s 2014 Bioprocessing and Sterile Manufacturing eBook

.

 

 

 

Articles in this issue
Continious-Biopharma185.jpg
Potential Benefits Drive Interest in Continuous Manufacturing
stephaniedubois200.jpg
Continuous Bioprocessing Challenges
PTebook0514_Cross-Contamination185.jpg
Determining Cross-Contamination Risks in Multiproduct Biopharmaceutical Facilities
PTebook0514_Continuous-Monitoring_1851431659146699.jpg
Achieving and Maintaining Compliance Using Continuous Monitoring Systems
PTebook0514_Telstar185.jpg
Optimizing the Sterilization of Liquids in Sealed Containers
par-almhelm200.jpg
Using Modular Systems in Biopharmaceutical Manufacturing
PTebook_Genzyme185.jpg
Determining Protein Oxidation Induced During Fill-Finish Operations
PTebook0514_SingleUse_185.jpg
Single-Use Technology in Parenteral Fill/Finish
Recent Videos
Behind the Headlines episode 6
Behind the Headlines episode 5
Buy, Sell, Hold: Cell and Gene Therapy
Buy, Sell, Hold: Cell and Gene Therapy
Related Content
Communication between the manufacturing plant and retail stores. | Image Credit: © Cagkan - © Cagkan - stock.adobe.com

Alentis Therapeutics to Advance Anti-Claudin-1 ADCs to Treat Solid Tumors on $181.4 Million Financing

Feliza Mirasol
November 19th 2024
Article

Financing from OrbiMed, Novo Holdings, Jeito Capital, and others will enable Alentis Therapeutics to advance its pipeline of Claudin-1-targeted ADCs for treating solid tumors.

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Felicity Thomas
June 25th 2024
Podcast

In this episode, Hanns-Christian Mahler from ten23 Health chats about the advances in fill/finish.

Communication between the manufacturing plant and retail stores. | Image Credit: © Cagkan - © Cagkan - stock.adobe.com

Newly Opened Innovation Center in New Jersey Gives Avantor Advantage in Solving Life Sciences Challenges

Feliza Mirasol
November 15th 2024
Article

Avantor's newly launched expanded Innovation Center in Bridgewater, NJ, is designed for integrated workflows and features purpose-built collaboration spaces.

Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development

Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development

March 26th 2024
Podcast

In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.

Communication between the manufacturing plant and retail stores. | Image Credit: © Cagkan - © Cagkan - stock.adobe.com

Merck and Ginkgo Bioworks’ Collaboration to Improve Biologics Manufacturing Has Reached Its First Milestone

Feliza Mirasol
November 13th 2024
Article

Under an ongoing partnership with Merck, known as MSD outside of the United States and Canada, Ginkgo Bioworks has achieved the first milestone in a project aimed at improving biologics production.

Communication between the manufacturing plant and retail stores. | Image Credit: © Cagkan - © Cagkan - stock.adobe.com

TrakCel’s OCELLOS Platform Selected to Support Treatment Management of Five Upcoming Cell Therapy Products

Feliza Mirasol
November 13th 2024
Article

Manufacturers of five autologous or matched allogenic cell therapy products have selected TrakCel's IT platform, OCELLOS, to orchestrate the administration of these therapies, which are approved or expected to be approved in 2024.